Business Description
Prostatype Genomics AB
ISIN : SE0023261532
Share Class Description:
OSTO:PROGEN: Ordinary SharesTotal Employee Number:
7Compare
Compare
Traded in other countries / regions
PROGEN.SwedenPGO0.Germany IPO Date
2020-11-03Description
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.71 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.41 | |||||
Beneish M-Score | 0.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -87.6 | |||||
3-Year EBITDA Growth Rate | 85.2 | |||||
3-Year EPS without NRI Growth Rate | 84 | |||||
3-Year FCF Growth Rate | 85.8 | |||||
3-Year Book Growth Rate | -80.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.93 | |||||
9-Day RSI | 38.98 | |||||
14-Day RSI | 41.45 | |||||
3-1 Month Momentum % | -49.56 | |||||
6-1 Month Momentum % | 53.33 | |||||
12-1 Month Momentum % | -55.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.44 | |||||
Quick Ratio | 0.43 | |||||
Cash Ratio | 0.37 | |||||
Days Sales Outstanding | 49.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -420.8 | |||||
Shareholder Yield % | -18.77 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -6555.05 | |||||
Net Margin % | -7492.09 | |||||
EBITDA Margin % | -6852.02 | |||||
FCF Margin % | -6269.53 | |||||
OCF Margin % | -4006.9 | |||||
ROE % | -138.38 | |||||
ROA % | -97.69 | |||||
ROIC % | -87.23 | |||||
3-Year ROIIC % | -24.22 | |||||
ROC (Joel Greenblatt) % | -10326.16 | |||||
ROCE % | -133.36 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 19.55 | |||||
PB Ratio | 0.96 | |||||
EV-to-EBIT | -0.5 | |||||
EV-to-EBITDA | -0.53 | |||||
EV-to-Revenue | 36.51 | |||||
EV-to-FCF | -0.65 | |||||
Price-to-GF-Value | 3.91 | |||||
Earnings Yield (Greenblatt) % | -198.55 | |||||
FCF Yield % | -146.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Prostatype Genomics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.594 | ||
| EPS (TTM) (kr) | -1.05 | ||
| Beta | 5.1595 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 568.83 | ||
| 14-Day RSI | 41.45 | ||
| 14-Day ATR (kr) | 0.147262 | ||
| 20-Day SMA (kr) | 0.49305 | ||
| 12-1 Month Momentum % | -55.34 | ||
| 52-Week Range (kr) | 0.28 - 2.28 | ||
| Shares Outstanding (Mil) | 59.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prostatype Genomics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prostatype Genomics AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-07-23 | In 22 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 09:30 | 0.47 (+1.95%) | ||
| General meeting for 2025 | 2026-06-22 15:00 | 0.64 (+0.00%) | ||
| Annual report for 2025 | 2026-06-09 | 0.50 (-7.78%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 1.40 (+12.50%) | ||
| Second quarter earnings results for 2025 | 2025-07-23 | 1.08 (+10.20%) | ||
| General meeting for 2024 | 2025-05-15 10:00 | 1.35 (+20.77%) | ||
| Annual report for 2024 | 2025-04-24 | 1.06 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-02-13 | 4.47 (+0.61%) | ||
| 0.001:1 Stock Split | 2024-10-31 | 6.50 (-7.69%) |
Show
Entries
Prostatype Genomics AB Frequently Asked Questions
What is Prostatype Genomics AB(OSTO:PROGEN)'s stock price today?
The current price of OSTO:PROGEN is kr0.43. The 52 week high of OSTO:PROGEN is kr2.28 and 52 week low is kr0.28.
When is next earnings date of Prostatype Genomics AB(OSTO:PROGEN)?
The next earnings date of Prostatype Genomics AB(OSTO:PROGEN) is 2026-07-23 Est..
Does Prostatype Genomics AB(OSTO:PROGEN) pay dividends? If so, how much?
Prostatype Genomics AB(OSTO:PROGEN) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| New multi-centre study in Spain shows very strong interim results for Prostatype® | 2023-10-25 |
Articles on Prostatype Genomics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers